Table 2.
Efficacy and safety profile of new agents in the treatment of advanced relapsed and refractory multiple myeloma.
| Selinexor 63 | Melflufen 64 | Belamaf 13 | Teclistamab 14 | Talquetamab 15 | Ide-cel 16 | Cilta-cel 65 | |
|---|---|---|---|---|---|---|---|
| Efficacy | |||||||
| ORR, % | 26 | 29 | 31 | 69 | 69 | 73 | 97 |
| CR, % | <2 | 1 | 8 | 26 | 19 | 33 | 67 |
| PFS, months | 3.7 | 4.2 | 2.8 | – | – | 8.8 | 77% at 12 months |
| OS, months | 8.6 | 11.6 | 13.7 | – | – | 19.4 | 88% at 12 months |
| Safety | |||||||
| Neutropenia, % | 40 | 82 | 20 | 57 | 47 | 91 | 91 |
| Grade ⩾3 | 21 | 79 | 12 | 46 | 31 | 89 | 91 |
| Thrombocytopenia, % | 73 | 82 | 24 | 40 | 32 | 63 | 79 |
| Grade ⩾3 | 58 | 76 | 19 | 22 | 13 | 52 | 60 |
| CRS, % | – | – | – | 55 | 54 | 84 | 95 |
| Grade ⩾3 | – | 0 | 3 | 5 | 4 | ||
| Neurotoxicity, % | – | – | – | 5 | 6 | 18 | 21 |
| Grade ⩾3 | – | 0 | 2 | 3 | 10 | ||
| Other | Fatigue 73% GI 72% | – | 71%, ocular keratopathy | – | – | – | – |
Belamaf, belantamab mafodotin; Cilta-cel, ciltacabtagene autoleucel; CR, complete response; CRS cytokine-release syndrome; GI, gastrointestinal; Ide-cel, idecabtagene vicleucel; ORR, overall response rate; OS, overall survival; PFS, progression-free survival.